OncologyOnline.net

Oncology Xagena

Xagena Mappa
Medical Meeting
Neurobase.it
Dermabase.it

In the phase 2 CheckMate 142 trial, Nivolumab ( Opdivo ) plus low-dose Ipilimumab ( Yervoy ) has provided robust and durable clinical benefit and was well tolerated as first-line therapy for microsate ...


The randomized, open-label, phase 3 KEYNOTE-426 study has demonstrated that Pembrolizumab ( Keytruda ) + Axitinib ( Inlyta ) significantly improved overall survival ( OS ), progression-free survival ( ...


Osimertinib ( Tagrisso ) is a 3rd-generation, CNS-active, epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor ( TKI ) [ EGFR-TKI ] with superior efficacy to comparator EGFR-TKI ( Gefit ...


Cemiplimab ( Libtayo ) monotherapy achieves clinically meaningful activity in patients with advanced cutaneous squamous cell carcinoma ( CSCC ) ( metastatic [ mCSCC ] or locally advanced [ laCSCC ] no ...


The highly selective TRK inhibitor Larotrectinib ( Vitrakvi ) is approved for the treatment of adult and pediatric cancers that harbor NTRK gene fusions; it achieves a 79% overall response rate ( ORR ...


Papillary renal cell carcinoma ( PRCC ) is the most common type of non-clear cell RCC, accounting for 10–15% of renal malignancies. As a subset of PRCC cases are MET-driven, MET inhibition may be an ...


Pembrolizumab ( Keytruda ) was approved for the treatment of high-risk ( HR ) non–muscle-invasive bladder cancer ( NMIBC ) based on results from the phase 2 KEYNOTE-057 trial. Researchers have pre ...


Patients with advanced B3 thymoma ( B3T ) and thymic carcinoma ( TC ) resistant to chemotherapy have limited treatment options. Treatment with anti-PD1 showed not negligible toxicity and limited act ...


Erdafitinib ( Balversa ) is a pan-FGFR kinase inhibitor for treatment of adults with metastatic urothelial carcinoma ( mUC ) with susceptible FGFR3/2 alterations and who progressed on 1 line or more o ...


In the phase 3, randomized, open-label CASPIAN study, first-line Durvalumab ( Imfinzi ) added to Etoposide plus either Cisplatin or Carboplatin ( EP ) significantly has improved overall survival ( OS ...


Myeloid-derived suppressor cells ( MDSC ) are expanded in cancer and promote immune suppression. A research has shown that Ibrutinib ( Imbruvica ) inhibits migration and immunosuppressive function o ...


NTRK gene fusions lead to transcription of chimeric TRK proteins with overexpressed kinase function. Entrectinib ( Rozlytrek ) is a potent inhibitor of TRKA/B/C. In phase 1/2 studies ( ALKA, STARTRK ...


SPARTAN has evaluated Apalutamide ( Erleada ) versus placebo in patients with nonmetastatic castration-resistant prostate cancer ( nmCRPC ) and a prostate-specific antigen ( PSA ) doubling time of les ...


In the ongoing, multicohort, phase 2 GEOMETRY mono-1 study, Capmatinib ( Tabrecta ) has shown efficacy in METex14–mutated non–small cell lung cancer ( NSCLC ) patients who were pretreated ( cohort 4 ) ...


While studies have demonstrated survival benefits of first-line regimens including immuno-oncology agents ( IO ) in advanced renal cell carcinoma ( aRCC ), optimal treatment following onco-immunothera ...